DermDx: Child With Rash Along Hairline
Clinical Advisor,
Slideshow A 5-year-old girl is referred by her pediatrician for evaluation of a spreading rash on her head.
Arctic Bioscience AS receives positive opinion on Paediatric Investigational Plan from the European Medicines Agency
MarketScreener,
, a biotechnology company developing and commercializing nutraceutical and pharmaceutical products based on the unique…
What to know about psoriasis
Medical News Today,
We include products we think are useful for our readers. If you buy through links on this page, we may earn a small commission.
Common Annular Lesions in the Pediatric Population: Part 1
Medical Health News,
Annular rashes are ring-like lesions that occur in a variety of conditions, including both cutaneous and systemic disorders.
Janssen Announces U.S. FDA Approval Of STELARA® (ustekinumab) For The Treatment Of Adolescents With Moderate To Severe Plaque Psoriasis
BioTech Gate,
HORSHAM, Pa., Oct. 13, 2017 /PRNewswire/ -- Janssen Biotech, Inc., announced today that the U.S.
Janssen Announces U.S. FDA Approval Of STELARA® (ustekinumab) For The Treatment Of Adolescents With Moderate To Severe Plaque Psoriasis
KTRE,
Information contained on this page is provided by an independent third-party content provider.
Janssen Announces U.S. FDA Approval Of STELARA® (ustekinumab) For The Treatment Of Adolescents With Moderate To Severe Plaque Psoriasis
2 News,
Information contained on this page is provided by an independent third-party content provider.
Janssen Announces U.S. FDA Approval Of STELARA® (ustekinumab) For The Treatment Of Adolescents With Moderate To Severe Plaque Psoriasis
WRCB- TV,
SOURCE Janssen Biotech - Approval of STELARA® for adolescents 12 years or older provides an important new treatment option for…
Janssen Announces U.S. FDA Approval Of STELARA® (ustekinumab) For The Treatment Of Adolescents With Moderate To Severe Plaque Psoriasis
Kuam,
SOURCE Janssen Biotech - Approval of STELARA® for adolescents 12 years or older provides an important new treatment option for…
Janssen Announces U.S. FDA Approval Of STELARA® (ustekinumab) For The Treatment Of Adolescents With Moderate To Severe Plaque Psoriasis
KFVE The Home Team,
SOURCE Janssen Biotech - Approval of STELARA® for adolescents 12 years or older provides an important new treatment option for…
Janssen Announces U.S. FDA Approval Of STELARA® (ustekinumab) For The Treatment Of Adolescents With Moderate To Severe Plaque Psoriasis
WAND 17,
SOURCE Janssen Biotech - Approval of STELARA® for adolescents 12 years or older provides an important new treatment option for…
Janssen Announces U.S. FDA Approval Of STELARA® (ustekinumab) For The Treatment Of Adolescents With Moderate To Severe Plaque Psoriasis
CBS8,
SOURCE Janssen Biotech - Approval of STELARA® for adolescents 12 years or older provides an important new treatment option for…
Janssen Announces U.S. FDA Approval Of STELARA® (ustekinumab) For The Treatment Of Adolescents With Moderate To Severe Plaque Psoriasis
WLOX,
SOURCE Janssen Biotech - Approval of STELARA® for adolescents 12 years or older provides an important new treatment option for…
Janssen Announces U.S. FDA Approval Of STELARA® (ustekinumab) For The Treatment Of Adolescents With Moderate To Severe Plaque Psoriasis
WFLX Fox 29,
SOURCE Janssen Biotech - Approval of STELARA® for adolescents 12 years or older provides an important new treatment option for…
Janssen Announces U.S. FDA Approval Of STELARA® (ustekinumab) For The Treatment Of Adolescents With Moderate To Severe Plaque Psoriasis
Ticker Tech,
HORSHAM, Pa., Oct. 13, 2017 /PRNewswire/ -- Janssen Biotech, Inc., announced today that the U.S.
Psoriasis in children: Symptoms, treatments, and causes
Medical News Today,
Finding out a child has psoriasis can be difficult news for any parent who will worry about the effects this lifelong skin…